EP Patent

EP3771716A1 — Low hygroscopic amorphous form of baricitinib

Assigned to Zaklady Farmaceutyczne Polpharma SA · Expires 2021-02-03 · 5y expired

What this patent protects

The invention relates to a low hygroscopic amorphous form of baricitinib and process for preparation thereof. It also refers to a pharmaceutical composition containing said amorphous form and to a use of said low hygroscopic amorphous form or pharmaceutical composition containing…

USPTO Abstract

The invention relates to a low hygroscopic amorphous form of baricitinib and process for preparation thereof. It also refers to a pharmaceutical composition containing said amorphous form and to a use of said low hygroscopic amorphous form or pharmaceutical composition containing it for the treatment of rheumatoid arthritis.

Drugs covered by this patent

Patent Metadata

Patent number
EP3771716A1
Jurisdiction
EP
Classification
—
Expires
2021-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Zaklady Farmaceutyczne Polpharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.